Myriad Genetics, Inc (NASDAQ:MYGN) has a beta value of 1.92 and has seen 1.65 million shares traded in the last trading session. The company, currently valued at $460.89M, closed the last trade at $5.0 per share which meant it lost -$0.22 on the day or -4.21% during that session. The MYGN stock price is -486.0% off its 52-week high price of $29.30 and 23.8% above the 52-week low of $3.81. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.06 million shares traded. The 3-month trading volume is 2.30 million shares.
The consensus among analysts is that Myriad Genetics, Inc (MYGN) is Hold stock at the moment, with a recommendation rating of 3.12. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 5 out of 7 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.01.
Myriad Genetics, Inc (NASDAQ:MYGN) trade information
Sporting -4.21% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the MYGN stock price touched $5.0 or saw a rise of 14.24%. Year-to-date, Myriad Genetics, Inc shares have moved -80.69%, while the 5-day performance has seen it change -9.91%. Over the past 30 days, the shares of Myriad Genetics, Inc (NASDAQ:MYGN) have changed -3.66%. Short interest in the company has seen 8.38 million shares shorted with days to cover at 3.6.
Wall Street analysts have a consensus price target for the stock at $9.75, which means that the shares’ value could jump 48.72% from current levels. The projected low price target is $6.0 while the price target rests at a high of $18.0. In that case, then, we find that the current price level is -260.0% off the targeted high while a plunge would see the stock gain -20.0% from current levels.
Myriad Genetics, Inc (MYGN) estimates and forecasts
The company’s shares have lost -66.28% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -3.05%.
13 analysts offering their estimates for the company have set an average revenue estimate of 202.3M for the current quarter. 13 have an estimated revenue figure of 204.5M for the next ending quarter. Year-ago sales stood 211.5M and 213.3M respectively for this quarter and the next, and analysts expect sales will shrink by -4.35% for the current quarter and -3.05% for the next.
Earnings growth for 2025 is a modest -106.08% while over the next 5 years, the company’s earnings are expected to increase by 24.07%.
MYGN Dividends
Myriad Genetics, Inc is expected to release its next earnings report on 2025-May-06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Myriad Genetics, Inc (NASDAQ:MYGN)’s Major holders
Insiders own 2.77% of the company shares, while shares held by institutions stand at 104.21% with a share float percentage of 107.18%. Investors are also buoyed by the number of investors in a company, with Myriad Genetics, Inc having a total of 327.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 15.15 million shares worth more than $370.59 million. As of 2024-06-30, BLACKROCK INC. held 16.7227% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 10.06 million shares as of 2024-06-30. The firm’s total holdings are worth over $246.18 million and represent 11.1089% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Trust-iShares Core S&P Small-Cap ETF and Vanguard Explorer Fund . As of May 31, 2025 , the former fund manager holds about 5.91% shares in the company for having 5.45 shares of worth $27.23 million while later fund manager owns 3.1 shares of worth $15.51 million as of Apr 30, 2025 , which makes it owner of about 3.37% of company’s outstanding stock.
